Clinical Trial Update: Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response [Phase 2]

View source ↗

Summary

Phase 2 trial of BMS-690514 in non-small cell lung cancer patients who are EGFR mutation positive or had prior response to gefitinib/erlotinib has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BMS-690514

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Non-Small-Cell Lung Carcinoma | Phase 2 | Status: COMPLETED